Please assess the completion status of the following clinical trial:

Trial Title: Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women between the ages of 18 to 70~* Meet DSM-IV (Diagnostic and Statistical Manual version IV) criteria for schizophrenia or schizoaffective disorder based on SCID (Structured Clinical Interview for the DSM-IV) interview~* Overweight, as defined with a BMI of equal to or greater than 27 kg/m² and continuing weight gain in the past year above 2% of previous years total body weight~* Be on a stable dose of antipsychotic medication; i.e. at least one month with no dosage change, and two months from an antipsychotic switch; 5) Deemed to be symptomatically stable by the clinical staff in the last two months~Exclusion Criteria:~* Meet criteria for current alcohol or other substance dependence, opioid use for any reason or positive urine drug screen for opiates~* A history of dementia, mental retardation or other neurological disorder that may interfere with study ratings~* Not capable of giving informed consent for participation in this study~* Ongoing pregnancy~* Known sensitivity to naltrexone~* A medical disorder that is known to cause obesity~* Use of sibutramine, topiramate, amphetamines or over the counter weight remedies~* Impaired liver functions (greater than 3 times the upper limit of normal)~* Diagnosed with polycystic ovary syndrome~* Currently being treated with insulin~* Current use of Depo-Provera or any natural/synthetic hormone treatment known to cause significant weight gain

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Naltrexone 25mg (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).